Whole Blood in Trauma Patients With Hemorrhagic Shock
Launched by FUNDACION CLINICA VALLE DEL LILI · Nov 21, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best way to treat trauma patients who are experiencing severe blood loss, known as hemorrhagic shock. Researchers want to compare two methods of providing blood transfusions: using whole blood (which includes all components of blood) versus using separate blood components like red blood cells, plasma, and platelets. The main goals are to see which method leads to lower death rates within 28 days and better overall health of the organs affected by the trauma.
To be eligible for this trial, participants need to be adults over 18 years old who are experiencing severe bleeding from trauma and are likely to need a large amount of blood transfusion. They must also be able to receive either whole blood or blood component therapy. However, certain patients are excluded, such as those with very severe injuries, those who have already received multiple blood transfusions, or pregnant individuals. If someone joins the study, they will receive one of the two types of blood treatment and will be monitored closely for their recovery and any changes in their health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (\> 18 years)
- • Activating institutional trauma code for trauma patients with hemorrhagic shock.
- • Candidate for massive transfusion (Patient with an Assessment Blood Consumption (ABC) Score ≥ 2 or at the discretion of the treating physician)
- • Concurrent availability of whole blood or blood component therapy
- Exclusion Criteria:
- • More than 4 hours from trauma to hospital admission
- • More than 2 hours from hospital admission to randomization
- • Transfusion of more than one packed red blood cell unit prior to randomization.
- • Patients who have undergone surgery (laparotomy, thoracotomy, or sternotomy) before hospital admission.
- • In-extremis patients with devastating injuries (expected to die within 60 minutes).
- • Blood group other than to O or A and positive Rh factor
- • Severe traumatic brain injury in which neurosurgical intervention is futile (partial decapitation, massive intracranial hemorrhage, or transcranial gunshot wounds).
- • Burns over 20% of the total body surface area.
- • Suspected airway burn.
- • Cardiopulmonary resuscitation (CPR) before arrival at the ED.
- • CPR for more than 5 minutes before randomization.
- • Do not resuscitate order.
- • Incarcerated/prisoners.
- • Known pregnancy in the ED.
- • Patient or legal representative who refuse to participate in clinical research studies.
About Fundacion Clinica Valle Del Lili
Fundación Clínica Valle del Lili is a leading healthcare institution located in Cali, Colombia, dedicated to advancing medical research and enhancing patient care through innovative clinical trials. As a sponsor, the foundation focuses on conducting high-quality, ethically-driven studies that contribute to the development of new treatments and therapies across various medical fields. With a commitment to excellence, the foundation collaborates with healthcare professionals and researchers to ensure rigorous methodologies and compliance with international standards, ultimately aiming to improve health outcomes and quality of life for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cali, Valle Del Cauca, Colombia
Patients applied
Trial Officials
Alberto F Garcia, MD MSc
Principal Investigator
Fundacion Clinica Valle del Lili
Carlos A Ordoñez, MD
Principal Investigator
Fundacion Clinica Valle del Lili
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials